MX2021004363A - Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa. - Google Patents

Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa.

Info

Publication number
MX2021004363A
MX2021004363A MX2021004363A MX2021004363A MX2021004363A MX 2021004363 A MX2021004363 A MX 2021004363A MX 2021004363 A MX2021004363 A MX 2021004363A MX 2021004363 A MX2021004363 A MX 2021004363A MX 2021004363 A MX2021004363 A MX 2021004363A
Authority
MX
Mexico
Prior art keywords
treatment
elr
hidradenitis suppurativa
pan
cxc chemokine
Prior art date
Application number
MX2021004363A
Other languages
English (en)
Inventor
Kristine Kay Kikly
Dipak Ratilal Patel
Derrick Ryan Witcher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021004363A publication Critical patent/MX2021004363A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporcionan métodos y usos de anticuerpos contra quimiocinas CXC ELR+ para el tratamiento de la hidradenitis supurativa. También se proporcionan dosis y regímenes de dosis para los métodos y usos de los anticuerpos contra las quimiocinas CXC ELR+ para el tratamiento de la hidradenitis supurativa.
MX2021004363A 2018-10-22 2019-10-15 Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa. MX2021004363A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748838P 2018-10-22 2018-10-22
US201962791061P 2019-01-11 2019-01-11
PCT/US2019/056250 WO2020086327A1 (en) 2018-10-22 2019-10-15 Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
MX2021004363A true MX2021004363A (es) 2021-05-31

Family

ID=68425364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004363A MX2021004363A (es) 2018-10-22 2019-10-15 Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa.

Country Status (16)

Country Link
US (1) US12037387B2 (es)
EP (1) EP3870288A1 (es)
JP (2) JP7171913B2 (es)
KR (2) KR20240014601A (es)
CN (1) CN112912140B (es)
AU (1) AU2019364239B2 (es)
BR (2) BR112021004900A2 (es)
CA (1) CA3117142A1 (es)
IL (1) IL282307A (es)
MA (1) MA53976A (es)
MX (1) MX2021004363A (es)
MY (1) MY197879A (es)
SG (1) SG11202102904TA (es)
TW (1) TWI737000B (es)
UA (1) UA128649C2 (es)
WO (1) WO2020086327A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014080A (es) * 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
TWI612059B (zh) * 2013-03-15 2018-01-21 美國禮來大藥廠 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
US9290570B2 (en) * 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
KR101418306B1 (ko) 2013-03-19 2014-07-15 김대운 바지의 흘러내림 방지용 버팀기둥
WO2015197098A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2016098071A1 (en) * 2014-12-18 2016-06-23 Csir Immunomodulation by controlling elr+ proinflammatory chemokine levels with the long non-coding rna umlilo
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa

Also Published As

Publication number Publication date
KR102628314B1 (ko) 2024-01-25
CN112912140A (zh) 2021-06-04
TWI737000B (zh) 2021-08-21
US20210340244A1 (en) 2021-11-04
CN112912140B (zh) 2024-08-20
WO2020086327A1 (en) 2020-04-30
JP2023011819A (ja) 2023-01-24
UA128649C2 (uk) 2024-09-18
JP7410256B2 (ja) 2024-01-09
EP3870288A1 (en) 2021-09-01
US12037387B2 (en) 2024-07-16
BR112021004900A2 (pt) 2021-06-01
KR20240014601A (ko) 2024-02-01
JP7171913B2 (ja) 2022-11-15
TW202028233A (zh) 2020-08-01
CA3117142A1 (en) 2020-04-30
KR20210060582A (ko) 2021-05-26
SG11202102904TA (en) 2021-05-28
AU2019364239A1 (en) 2021-04-22
MA53976A (fr) 2022-01-26
IL282307A (en) 2021-05-31
JP2022512721A (ja) 2022-02-07
BR122023023399A2 (pt) 2024-02-20
AU2019364239B2 (en) 2023-02-02
MY197879A (en) 2023-07-22

Similar Documents

Publication Publication Date Title
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
BR112018012145A2 (pt) partículas de entrega de pró-sabor
MX2018016364A (es) Anticuerpos anti-pd-l1.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
PH12020551716A1 (en) Anti-ror antibody constructs
BR112019002371A2 (pt) composições farmacêuticas
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2018003297A (es) Aplicador de precision.
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
MX2019012865A (es) Anticuerpos anti-interferon gamma y usos de los mismos.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MY187366A (en) A method of treating hair using a composition comprising an alpha-substituted aldehyde
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2023006458A (es) Oligosacaridos inmunomoduladores.
CR20220355A (es) Compuestos activos frente a receptores nucleares
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
PH12017501930A1 (en) Calicheamicin contructs and methods of use
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MY197879A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso